Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least s
How this was made
The 30-second read
Why it matters
The filing provides the first public glimpse of Phase 1 results and a sizable upfront payment, likely prompting short‑term price movement.
Market read
New clinical data and cash infusion create a fresh catalyst for GENB, making the filing highly relevant for traders.
What to watch
Potential dilution from future milestone payments and the need for later‑stage trial success.
Generate Biomedicines reports Q3 2026 net loss of $87.7 million on collaboration revenue of $4.2 million; cash, equivalents and marketable securities fell to $404.2 million
Clinical and partnering progress was reported across GB-0895, the Zealand and Anthropic collaborations and the oncology pipeline. Quarterly revenue fell from $9.6 million to $4.2 million, the net loss widened from $60.0 million to $87.7 million, and cash and marketable securities declined from $457.4 million at June 30, 2026 to $404.2 million at Sept. 30, 2026.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, Q3 2026 (three months ended Sept. 30, 2026)GAAP | $4.2M | – | – |
| Collaboration revenue, nine months ended Sept. 30, 2026GAAP | $17.76M | – | – |
| Research and development expenses, Q3 2026GAAP | $82.3M | – | – |
| Research and development expenses, nine months ended Sept. 30, 2026GAAP | $204.4M | – | – |
| General and administrative expenses, Q3 2026GAAP | $13.5M | – | – |
| General and administrative expenses, nine months ended Sept. 30, 2026GAAP | $40.59M | – | – |
| Total operating expenses, Q3 2026GAAP | $95.73M | – | – |
| Total operating expenses, nine months ended Sept. 30, 2026GAAP | $245.0M | – | – |
| Loss from operations, Q3 2026GAAP | −$91.51M | – | – |
| Loss from operations, nine months ended Sept. 30, 2026GAAP | −$227.2M | – | – |
| Interest income, Q3 2026GAAP | $4.15M | – | – |
| Interest income, nine months ended Sept. 30, 2026GAAP | $11.69M | – | – |
| Interest expense, Q3 2026GAAP | −$192K | – | – |
| Interest expense, nine months ended Sept. 30, 2026GAAP | −$529K | – | – |
| Total other income (expense), net, Q3 2026GAAP | $3.90M | – | – |
| Provision for income taxes, Q3 2026GAAP | −$49K | – | – |
| Net loss, Q3 2026GAAP | $87.7M | – | – |
| Net loss, nine months ended Sept. 30, 2026GAAP | −$216.6M | – | – |
| Net loss attributable to Generate Biomedicines, Inc. common stockholders, Q3 2026GAAP | −$87.66M | – | – |
| Net loss attributable to Generate Biomedicines, Inc. common stockholders, nine months ended Sept. 30, 2026GAAP | −$224.1M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(0.68) | – | – |
| Net loss per share, basic and diluted, nine months ended Sept. 30, 2026GAAP | $(2.09) | – | – |
| Noncash stock-based compensation expense, Q3 2026other | $8.1M | – | – |
| Cash, cash equivalents and marketable securities as of Sept. 30, 2026other | $404.2M | – | – |
| Total assets as of Sept. 30, 2026GAAP | $515.9M | – | – |
| Total stockholders' equity as of Sept. 30, 2026GAAP | $381.2M | – | – |
Capital returns
- No share repurchases or dividends are reported. Common shares outstanding were 129,021,869 as of Sept. 30, 2026, against 33,116,957 as of Dec. 31, 2025, and the filing does not describe the issuance.
What drove it
- Management attributes the R&D increase, from $62.2 million to $82.3 million, primarily to continued investment in the GB-0895 Phase 3 SOLAIRIA clinical trials in severe asthma. The company states this was partially offset by a decrease in external discovery and other program related costs.
- Management attributes the G&A increase, from $10.3 million to $13.5 million, primarily to an increase in stock-based compensation.
- Management states that collaboration revenue reflects ongoing Amgen and Novartis research programs and that Generate is near completion of its performance obligations under both agreements.
- Net loss attributable to noncash stock-based compensation expense of $8.1 million in Q3 2026 and $4.8 million in Q3 2025, as stated in the release.
- Pipeline events in the period: GB-4362 advanced to the second of potentially three dose-escalation cohorts; first patient dosed in the GB-5267 Phase 1 study in platinum-resistant ovarian cancer; Zealand collaboration signed Oct. 13; Anthropic collaboration announced Oct. 27.
Concerns
- Collaboration revenue fell from $9.6 million in Q3 2025 to $4.2 million in Q3 2026, and the filing says the Amgen and Novartis programs are near completion of their performance obligations.
- Net loss rose from $60.0 million to $87.7 million, and loss from operations rose from $(62,812) thousand to $(91,507) thousand.
- Cash, cash equivalents and marketable securities declined from $457.4 million at June 30, 2026 to $404.2 million at Sept. 30, 2026.
- Management states that the company expects to require additional capital to support long-term operations.
- The stated runway into the first half of 2028 depends in part on the $30.0 million Zealand upfront payment and the existing cash balance.
What to watch
- Enrollment and dosing in cohort 2 of GB-4362 and the progress of the GB-5267 Phase 1 study in ovarian cancer.
- Progress of the SOLAIRIA-1 and SOLAIRIA-2 Phase 3 studies of GB-0895 in severe asthma, and the timing of any decision on developing GB-0895 in COPD.
- Whether collaboration revenue stabilizes after the Amgen and Novartis programs near completion, and whether new collaboration revenue is recognized.
- Zealand milestone payments, including the $35 million in early preclinical milestones, and the Anthropic research collaboration results.
- Cash burn against the cash balance and any financing disclosed ahead of the stated first half of 2028 runway.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $404.2 million as of Sept. 30, 2026, compared with $457.4 million as of June 30, 2026.
- Cash and cash equivalents were $140,350 thousand and marketable securities were $263,862 thousand as of Sept. 30, 2026. The Dec. 31, 2025 comparatives were $121,650 thousand and $99,848 thousand.
- Total assets were $515,890 thousand as of Sept. 30, 2026, against $330,182 thousand as of Dec. 31, 2025. Total stockholders' equity was $381,156 thousand, against a deficit of $(615,965) thousand as of Dec. 31, 2025.
- Generate states that its existing cash, cash equivalents and marketable securities, together with the $30.0 million upfront payment received from Zealand in October 2026, will be sufficient to fund its current operating plan into the first half of 2028. It also states that it expects to require additional capital to support long-term operations.
- The Zealand agreement provides $30 million upfront, up to $35 million in early preclinical milestones within nearly $1.2 billion in total potential milestone payments, and tiered royalties. Generate states the upfront was received in October 2026, after the quarter end.
- The filing reports no operating cash flow, investing cash flow or free cash flow figures.
Analysis
Generate reported third quarter 2026 collaboration revenue of $4.2 million, against $9.6 million in the same period of 2025. The company says this revenue reflects its Amgen and Novartis research programs and that it is near completion of its performance obligations under both. Revenue for the nine months was $17,758 thousand, against $28,582 thousand a year earlier. On the cost side, research and development expenses rose to $82.3 million from $62.2 million, and general and administrative expenses rose to $13.5 million from $10.3 million. The company attributes the R&D increase primarily to the GB-0895 Phase 3 SOLAIRIA trials in severe asthma, partly offset by lower external discovery and other program costs, and the G&A increase primarily to stock-based compensation. Total operating expenses were $95,727 thousand, and the loss from operations was $(91,507) thousand, against $(62,812) thousand in the prior year quarter.
Net loss was $87.7 million for the quarter, compared with $60.0 million, and the net loss per share was $(0.68), against $(1.97). The filing prints these loss figures on a GAAP basis and reports no non-GAAP measures. Interest income of $4,149 thousand partly offset operating losses, and noncash stock-based compensation was $8.1 million, against $4.8 million. The release reports no segment breakdown, so the revenue decline cannot be attributed to a segment within the filing.
On the balance sheet, cash, cash equivalents and marketable securities were $404.2 million at Sept. 30, 2026, down from $457.4 million at June 30, 2026. Total assets were $515,890 thousand and stockholders' equity was $381,156 thousand, against a deficit of $(615,965) thousand at Dec. 31, 2025, a change the filing does not explain in detail. Generate states that existing resources plus the $30.0 million Zealand upfront payment received in October 2026 will fund its current operating plan into the first half of 2028, and that it expects to need additional capital for long-term operations. The filing gives no operating or free cash flow figures and no financial guidance.
On the pipeline, the company reports complete Phase 1 data showing sustained biomarker suppression for at least six months for GB-0895 in asthma and COPD, and the SOLAIRIA Phase 3 studies continue with a 300 mg dose every 26 weeks. The Zealand agreement covers two initial multispecific programs for obesity and metabolic disease, with Generate leading research through lead-candidate selection. The Anthropic collaboration reports a CAR signaling domain about 70% shorter than the comparison design, with improved tumor-cell killing in laboratory tests, though this is early preclinical work. The read for investors is that clinical and partnering activity advanced during the quarter, while revenue declined, the loss widened and cash fell, with the runway resting on continued funding beyond the reported cash balance.
Management, verbatim
We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing.
Mike Nally, chief executive officer of Generate Biomedicines
Under the Zealand agreement, Generate received a $30 million upfront payment in October, may receive additional near-term milestones, and is now partnered to explore multispecific protein therapeutics for obesity and metabolic disease.
Jason Silvers, president and chief financial officer of Generate Biomedicines
Not in the filing
stated, not guessed- Company financial guidance for revenue, operating expenses or other metrics (no guidance is provided in the filing)
- Percentage changes year over year for revenue, R&D, G&A, net loss and cash, which are not printed
- Operating cash flow, investing cash flow and free cash flow for the period
- Segment or geographic revenue breakdown
- Prior-year balance sheet comparatives for the Sept. 30, 2025 quarter-end (only Dec. 31, 2025 comparatives are printed)
- Prior-year cash, cash equivalents and marketable securities balance (only the June 30, 2026 balance is printed)
- Adjusted or non-GAAP net loss or operating loss
- Consensus estimates and share price reaction (not in the filing)
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Generate Biomedicines filed an 8‑K reporting Q3 financials, early trial data for its lead candidate GB‑0895, and a new partnership with Zealand Pharma.
Ticker impact
SEC 8‑K discloses Q3 2026 results, Phase 1 asthma/COPD data for GB‑0895 and a $30 M upfront collaboration with Zealand Pharma.
likely upward pressure as investors price in new data and partnership cash.
First public disclosure of Phase 1 results and a $30 M deal provides fresh material that can move the share price immediately.
Market effects
Biotech sector may see renewed interest in AI‑engineered antibodies and respiratory therapeutics.
US biotech investors likely respond; no direct regional effect.
Collaboration with Zealand Pharma adds a European partner, modest global relevance.
Counterpoint
Phase 1 data are early; efficacy and safety still unproven, cash burn could pressure valuation.
Key entities
- companyGenerate Biomedicines, Inc.
US‑listed biotech developing AI‑engineered therapeutics.
- companyZealand Pharma
Partner in obesity/metabolic disease therapeutics collaboration.
